SARS-CoV-2

In any normal year, an academic debate about the efficacy of a certain drug to treat an infection would never garner media attention. But this isn't a normal year.

After the coronavirus crept out of China earlier this year, Europe became the epicenter of the pandemic. In response, nations across the continent implemented fairly harsh lockdowns.

Several months ago, there was speculation that SARS-CoV-2, the coronavirus that causes COVID-19, was created in a Chinese bioweapons laboratory.

Dr. Katherine Seley-Radtke, a professor of chemistry and biochemistry at the University of Maryland, Baltimore County is an expert in antiviral drug discovery, and a member of the ACSH Scientific Advisory Board. Dr.

I recently wrote about two products, both Lysol sprays, which got the nod from the EPA to make an anti-COVID claim, but noted that there

While Americans were (sort of) celebrating the Fourth of July, the coronavirus kept raging on. Some relevant developments and analysis have occurred in the past few days that might shed a little more light on how the pandemic will unfold.

Several months into the coronavirus pandemic, we still don't have a good understanding of SARS-CoV-2. The often contradictory information we get from scientists and public health officials reflects this.

There are a plethora of drugs and vaccines in the pipeline to treat or prevent COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2. How many of them are likely to be successful?